Lilly's Zepbound and Taltz Combo Shows Promise for Psoriatic Arthritis and Obesity
TL;DR Summary
Eli Lilly's Phase 3b trial shows that combining Taltz (ixekizumab) and Zepbound (tirzepatide) significantly improves outcomes in adults with psoriatic arthritis and obesity, meeting primary and secondary efficacy endpoints and suggesting a potential new integrated treatment approach.
- Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight Eli Lilly
- Lilly touts promise of Zepbound-Taltz combo in patients with obesity and psoriatic arthritis Fierce Pharma
- Eli Lilly’s Zepbound, on top of immunology drug, helped reduce psoriatic arthritis symptoms statnews.com
- Weight Loss Drugs Like Zepbound Could Help Treat Arthritis, Trial Shows Gizmodo
- Lilly’s Zepbound plus Taltz boosts arthritis relief, weight loss in late-stage trial Reuters
Reading Insights
Total Reads
0
Unique Readers
4
Time Saved
18 min
vs 19 min read
Condensed
99%
3,620 → 37 words
Want the full story? Read the original article
Read on Eli Lilly